Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Pascual, Aurélie ^a,b   Parola, Philippe ^c   Benoit Vical, Françoise ^d   Simon, Fabrice ^e   Malvy, Denis ^f   Picot, Stéphane ^g   Delaunay, Pascal ^h   Basset, Didier ⁱ   Maubon, Danièle ^j   Faugère, Bernard ^k   Ménard, Guillaume ^l   Bourgeois, Nathalie ^m   Oeuvray, Claude ⁿ   Didillon, Eric ^o   Rogier, Christophe ^a   Pradines, Bruno ^a,b  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b Centre National de Reference du Paludisme   (France)

^c HÔPITAL NORD   (France)

^d CHU RANGUEIL   (France)

^e LAVERAN MILITARY TEACHING HOSPITAL   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g CNRS   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

^k TIMONE HOSPITAL   (France)

^l Military Teaching Hospital Sainte Anne   (France)

^m DEPARTMENT OF NEUROLOGY   (France)

ⁿ Medicines for Malaria Venture   (Switzerland)

^o Fulcrum Pharma (Europe) Ltd   (United Kingdom)

more..

Author keywords

Anti malarial; In vitro; Malaria; Piperaquine; Plasmodium falciparum; Pyronaridine; Resistance

Indexed keywords

ARTEMISINIC ACID; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; HYPOXANTHINE; MEFLOQUINE; PIPERAQUINE; PYRONARIDINE; QUININE; ANTIMALARIAL AGENT; NAPHTHYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; TRITIUM;

AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG SENSITIVITY; EX VIVO STUDY; IC 50; INDIA; NONHUMAN; PLASMODIUM FALCIPARUM; THAILAND; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY;

AFRICA; ANTIMALARIALS; DRUG RESISTANCE; HUMANS; HYPOXANTHINE; INDIA; INHIBITORY CONCENTRATION 50; NAPHTHYRIDINES; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; QUINOLINES; THAILAND; TRITIUM;

EID: 84857008805     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-45     Document Type: Article

References (58)

1. Antimalarial drug resistance. Le Bras J, Musset L, Clain J, Med Mal Infect 2006 36 401 405 10.1016/j.medmal.2006.05.005 16854546 (Pubitemid 44425394)
2. Preventing antimalarial drug resistance through combinations. White NJ, Drug Resist Update 2001 1 3 9
3. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Eastman RT, Fidock DA, Nat Rev Microbiol 2009 7 864 874 19881520
4. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in the Gambian children: a double-blind, randomized, controlled trial. Von Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebechi C, Gosling R, Coleman R, Ude JI, Sadiq A, Duraisingh M, Warhurst D, Alloueche A, Target G, Mcadam K, Greenwood B, Walraven G, Olliaro P, Doherty T, Lancet 2000 355 352 357 10.1016/S0140-6736(99)10237-X 10665554
5. Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Senegal. Brasseur P, Agnamey P, Gaye O, Vaillant M, Taylor WRJ, Olliaro PL, Malar J 2007 6 150 10.1186/1475-2875-6-150 18005408 (Pubitemid 351143782)
6. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H, PLoS One 2008 3 2390 10.1371/journal.pone.0002390
7. An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Ashley EA, Lwin KM, Mcgready R, Simon WH, Phaiphun L, Proux S, Wangseang N, Taylor W, Stepniewska K, Nawamaneerat W, Thwai KL, Barends M, Leowattana W, Olliaro P, Singhasivanon P, White NJ, Nosten F, Trop Med Int Health 2006 11 1653 1660 10.1111/j.1365-3156. 2006.01724.x 17054744 (Pubitemid 44624367)
8. An open label, randomised trial of artesunate + amodiaquine, artesunate + chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK, Gyapong J, Greenwood B, Chandramohan D, PloS One 2008 3 2530 10.1371/journal.pone.0002530
9. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Arinaitwe E, Sandison TG, Wanzira H, Kahuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G, Clin Infect Dis 2009 49 1629 1637 10.1086/647946 19877969
10. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SSS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Sik Shin C, Fleckenstein L, Lancet 2010 375 1457 1467 10.1016/S0140-6736(10)60322-4 20417857
11. Changes in the treatment responses to artesunate-mefloquine on the Northwestern border of Thailand during 13 years of continuous deployment. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F, PloS One 2009 4 4451 10.1371/journal.pone.0004451
12. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwrong M, Chotivanish K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
13. Evidence of artemisinin-resistant malaria in western Cambodia. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, N Engl J Med 2008 359 2619 2620 10.1056/NEJMc0805011 19064625
14. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C, Malar J 2009 8 10 10.1186/1475-2875-8-10 19138388
15. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. Nawaz F, Nsobya SL, Kiggundu M, Joloba M, Rosenthal PJ, J Infect Dis 2009 200 1650 1657 10.1086/647988 19905933
16. Synchronization of Plasmodium falciparum erythrocytic stages in culture. Lambros C, Vanderberg JP, J Parasitol 1979 65 418 420 10.2307/3280287 383936 (Pubitemid 10222999)
17. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, Garnotel E, Pradines B, Fusai T, Wade B, Adehossi E, Parola P, Kamil MA, Puijalon O, Rogier C, Am J Trop Med Hyg 2006 74 953 959 16760503 (Pubitemid 351627399)
18. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, M' Baye PS, Sane M, Thiam M, Gueye PM, Wade B, Touze JE, Debonne JM, Rogier C, Fusai T, Am J Trop Med Hyg 2006 75 146 151 16837722 (Pubitemid 351627584)
19. Activity of pyronaridine and mepacrine against twelve strains of Plasmodium falciparum in vitro. Elueze EI, Croft SL, Warhurst DC, J Antimicrob Chemother 1996 37 511 518 10.1093/jac/37.3.511 9182108 (Pubitemid 26116966)
20. Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum. Pradines B, Briolant S, Henry M, Oeuvray C, Baret E, Amalvict R, Didillon E, Rogier C, Malar J 2010 9 337 10.1186/1475-2875-9-337 21092326
21. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Looareesuwan S, Kyle DE, Vivaran C, Vanijanonta S, Wilairatana P, Wernsdorfer WH, Am J Trop Med Hyg 1996 54 205 209 8619449 (Pubitemid 26084442)
22. In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Ringwald P, Moukoko Eboumbou CE, Bickii J, Basco LK, Antimicrob Agents Chemother 1999 43 1525 1527 10348789 (Pubitemid 29259362)
23. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Kurth F, Pongratz P, Bélard S, Mordmüller B, Kremsner PG, Ramharter M, Malar J 2009 8 79 10.1186/1475-2875-8-79 19389221
24. In vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, Trape JF, Doury JC, J Antimicrob Chemother 1998 42 333 339 10.1093/jac/42.3.333 9786473 (Pubitemid 28442447)
25. In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine. Pradines B, Mabika Mamfoumbi M, Parzy D, Owono Medang M, Lebeau C, Mourou Mbina JR, Doury JC, Kombila M, Am J Trop Med Hyg 1999 60 105 108 9988332 (Pubitemid 29066013)
26. In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. Pradines B, Tall A, Ramiandrasoa F, Spiegel A, Sokhna C, Fusai T, Mosnier J, Daries W, Trape JF, Kunesch G, Parzy D, Rogier C, J Antimicrob Chemother 2006 57 1093 1099 10.1093/jac/dkl117 16595639 (Pubitemid 44644410)
27. In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium viva. Price RN, Marfurt J, Chalfein F, Kenagalem E, Piera KA, Tjitra E, Anstey NM, Russel B, Antimicrob Agents Chemother 2010 54 5146 5150 10.1128/AAC.00801-10 20876370
28. In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs. Davis TM, Hamzah J, Ilett KF, Karunajeewa HA, Reeder JC, Batty KT, Hackett S, Barrett PHR, Antimicrob Agents Chemother 2006 50 2883 2885 10.1128/AAC.00177-06 16870794 (Pubitemid 44198722)
29. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Vivas L, Rattray L, Stewart L, Bongard E, Robinson BL, Peters W, Croft SL, Acta Trop 2008 105 222 228 10.1016/j.actatropica.2007.12.005 18279817
30. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Bélard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordmüller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kremsner PG, J Infect Dis 2008 198 911 919 10.1086/591096 18694333
31. In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum. Childs GE, Hausler B, Milhous W, Chen C, Wimonwattrawatee T, Pooyindee N, Boudreau EF, Am J Trop Med Hyg 1988 38 24 29 3277460 (Pubitemid 18036107)
32. In vitro activity of pyronaridine against African strains of Plasmodium falciparum. Basco LK, Le Bras J, Ann Trop Med Parasitol 1992 86 447 454 1288425 (Pubitemid 23040784)
33. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P, Malar J 2011 10 268 10.1186/1475-2875-10-268 21923936
34. In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs. Davis TME, Hamzah J, Illett KF, Karunajeewa HA, Reeder JC, Batty KT, Hackett S, Barrett PHR, Antimicrob Agents Chemother 2006 50 2883 2885 10.1128/AAC.00177-06 16870794 (Pubitemid 44198722)
35. Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains. Fivelman QL, Adagu IS, Warhurst DC, Antimicrob Agents Chemother 2007 51 2265 2267 10.1128/AAC.01479-06 17404003 (Pubitemid 46903134)
36. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Muangnoicharoen S, Johnson DJ, Looareesuwan S, Krudsood S, Ward SA, Antimicrob Agents Chemother 2009 53 1362 1366 10.1128/AAC.01656-08 19188388
37. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Snyder C, Chollet J, Santo-Tomas J, Scheurer C, Wittlin S, Exp Parasitol 2007 115 296 300 10.1016/j.exppara.2006.09. 016 17087929 (Pubitemid 44828070)
38. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, Mcgready R, Ashton M, Nosten F, White NJ, Antimicrob Agents Chemother 2008 52 1052 1061 10.1128/AAC.00955-07 18180343 (Pubitemid 351358388)
39. An open-label, randomized study of dihidroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. Valecha N, Pyae Phyo A, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BHK, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukittayakamee S, PloS One 2010 5 11880 10.1371/journal.pone.0011880
40. A randomized controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. Grande T, Bernasconi A, Erhart A, Gamboa D, Casapia M, Delgado C, Torres K, Fanello C, Llanos-Cuentas A, D'Alessandro U, PLoS One 2007 10 1101
41. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, Day NPJ, Singhasivanon P, White NJ, Kaker F, Malar J 2010 9 105 10.1186/1475-2875-9-105 20409302
42. Piperaquine: a resurgent antimalarial drug. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF, Drugs 2005 65 75 87 10.2165/00003495-200565010-00004 16335861
43. Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Briolant S, Henry M, Oeuvray C, Amalvict R, Baret E, Didillon E, Rogier C, Pradines B, Antimicrob Agents Chemother 2010 54 3537 3544 10.1128/AAC.00183-10 20547801
44. In vitro activity of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Basco LK, Ringwald P, Antimicrob Agents Chemother 2003 47 1391 1394 10.1128/AAC.47.4.1391-1394.2003 12654675 (Pubitemid 36368602)
45. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Barends M, Jaidee A, Khaohirun N, Singhasivanon P, Nosten F, Malar J 2007 6 81 10.1186/1475-2875-6-81 17597537 (Pubitemid 47203009)
46. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A, Antimicrob Agents Chemother 2009 55 5069 5073
47. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ, Antimicrob Agents Chemother 2010 54 1200 1206 10.1128/AAC.01412-09 20065051
48. Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piear KA, MacHunter B, Tjitra E, Anstey NM, Price RN, Antimicrob Agents Chemother 2011 55 4461 4464 10.1128/AAC.01375-10 21730116
49. In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea. Wong RP, Lautu D, Tavul L, Hackett SL, Siba P, Karunajeewa HA, Ilett KF, Mueller I, Davis TM, Trop Med Int Health 2010 15 342 349 10.1111/j.1365-3156.2009.02463.x 20070627
50. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Eastman RT, Dharia NV, Winzeler EA, Fidock DA, Antimicrob Agents Chemother 2011 55 3908 3916 10.1128/AAC.01793-10 21576453
51. Efficacy and safety of dihydroartemisinin-piperaquine. Myint HY, Ashley EA, Day NPJ, Nosten F, White NJ, Trans R Soc Trop Med Hyg 2007 101 858 866 10.1016/j.trstmh.2007.05.018 17659311 (Pubitemid 47091464)
52. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HLE, Kenangalem E, Lindegardh N, Penttinen P, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Antimicrob Agents Chemother 2007 51 4090 4097 10.1128/AAC.00486-07 17846129 (Pubitemid 350057809)
53. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. Kamya MR, Yeka A, Burkirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Plos Clin Trials 2007 2 20 10.1371/journal.pctr. 0020020 (Pubitemid 46860146)
54. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina-Faso. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ, Ouédraogo JB, Clin Infect Dis 2007 45 1453 1461 10.1086/522985 17990228 (Pubitemid 351411875)
55. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug resistant Plasmodium falciparum and Plasmodium viva malaria. Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PMP, Laihad F, Anstey NM, Tjitra E, Price RN, Clin Infect Dis 2008 44 1067 1074 (Pubitemid 46580274)
56. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, Lin E, Lammey J, Batty KT, Davis TME, Antimicrob Agents Chemother 2008 52 237 243 10.1128/AAC.00555-07 17967917
57. Pitfalls in estimating piperaquine elimination. Tarning J, Lindegardh N, Annerberg A, Singtoroj T, Day NPJ, Ashton M, White NJ, Antimicrob Agents Chemother 2005 49 5127 5128 10.1128/AAC.49.12.5127-5128.2005 16304183 (Pubitemid 41778931)
58. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Ezzet F, Mull R, Karbwang J, Br J Clin Pharmacol 1998 46 553 561 9862244 (Pubitemid 28522119)